Bottom line
In response to public and political pressure on GLP-1 pricing, both major manufacturers now run direct-to-consumer programs for cash-paying patients:
- LillyDirect — Eli Lilly's program, covering Zepbound (and
to a lesser extent Mounjaro). Single-dose vial pricing for Zepbound starts around $349/month for the lowest dose.
- NovoCare — Novo Nordisk's program for Wegovy. Pricing is
comparable, with Wegovy available at a flat monthly cash price for self-pay patients.
These are not the same as a telehealth program. Both manufacturers route prescriptions through partner telehealth providers (LillyDirect uses a few partners; NovoCare similarly). What you're paying for is the manufacturer's brand-name drug at a meaningfully discounted cash price — not a different kind of care.
If your insurance covers your GLP-1 with a low copay, neither program is relevant to you. If your insurance excludes weight loss drugs and you're paying cash, both deserve serious consideration.
[program:lillydirect]
What each program is, exactly
LillyDirect (Zepbound and Mounjaro) launched in early 2024 as Lilly's direct channel to patients. The Zepbound piece of the program is the substantial one in 2026:
- Zepbound is sold in single-dose vials (not pens) at a flat
monthly cash price that scales by dose
- Pricing as of early 2026: roughly $349/month at 2.5 mg,
scaling up to roughly $549/month at 10 mg and higher doses
- Telehealth visit to obtain the prescription is required and is
routed through Lilly's partner network (FORM Health, 9amHealth, and others)
- The medication ships from a Lilly-affiliated pharmacy with
cold-chain handling
- Mounjaro pricing is more limited — manufacturer cash pricing
for Mounjaro depends on your savings card status
NovoCare (Wegovy) is Novo Nordisk's direct-pay channel. Structure is similar:
- Wegovy at a flat monthly cash price for self-pay patients,
generally in the $499–$649/month range depending on dose
- Telehealth visit through partner providers
- Brand-name pen, full Novo Nordisk packaging
- Patient must be self-pay and not seeking insurance
reimbursement for the same fill
Both programs require you to be 18 or older and to clear a clinical screening. Neither covers patients on Medicare or Medicaid (federal programs prohibit manufacturer cash discounts for these patients).
Price comparison, head to head
The exact cash price moves quarterly and varies by dose. As of the most recent data in 2026, the rough comparison looks like:
For early dosing (2.5 mg–5 mg starting and titration):
- LillyDirect Zepbound: $349/month
- NovoCare Wegovy: $499/month
For maintenance dosing (10 mg+ Zepbound, 1.7+ mg Wegovy):
- LillyDirect Zepbound: $499–$549/month
- NovoCare Wegovy: $599–$649/month
Both prices include the medication only. The required telehealth visit through the partner network is typically $25–$99 depending on the partner.
For the average patient at maintenance dose, LillyDirect Zepbound is roughly $50–$150/month cheaper than NovoCare Wegovy. That gap has narrowed over the last year as Novo has adjusted its cash pricing.
Which drug, separate from which program
The pricing comparison only matters if both drugs are clinically appropriate for you. The head-to-head trial data favors tirzepatide (Zepbound) for total weight loss:
- SURMOUNT-5 directly compared tirzepatide and semaglutide for
weight loss and showed meaningfully greater weight loss with tirzepatide at peak doses.
- Side effect profiles are similar but distinct — some
patients tolerate one molecule better than the other.
If you're starting from scratch with no preference and pure self-pay, Zepbound through LillyDirect is the value pick: better head-to-head data, lower cash price.
If you're already established on Wegovy and tolerating it well, switching for $50–$100/month is rarely worth the side-effect re-titration.
How the experience compares
We signed up for both programs in early 2026 and ran through the intake.
LillyDirect intake (Zepbound)
- Online questionnaire took about 15 minutes
- Asynchronous review by partner telehealth provider, decision
in 1–3 business days
- BMI documentation required — they accept self-reported
height and weight at this stage
- Vials shipped via overnight cold chain, arrival on day 4
after approval
- Vial-and-syringe administration (you draw the dose yourself
and inject) — different from the auto-injector pen many patients started on. Lilly provides syringes and clear instructions; some patients find this more intimidating initially but adapt within 2–3 weeks.
NovoCare intake (Wegovy)
- Online questionnaire similar length
- Telehealth visit (sometimes synchronous video, sometimes
asynchronous depending on partner) — decision in 1–5 business days
- BMI documentation required
- Pen shipped via overnight cold chain, arrival on day 5
after approval
- Standard Wegovy pen — same device, same training as the
pharmacy-dispensed product
The Wegovy pen is meaningfully easier to use than the LillyDirect vials for first-time GLP-1 patients. For patients comfortable with self-injection, the price savings on LillyDirect is the deciding factor for most.
Hidden costs and gotchas
A few things both programs do not include:
Lab work. Most prescribers in both partner networks request basic labs (HbA1c, comprehensive metabolic panel, lipid panel) before starting and at the 3-month mark. These are not included in either program. Through Quest or Labcorp self-pay, expect $80–$200 per round of labs. Insurance often covers labs even when it doesn't cover the drug.
Side effect management. No nutritionist, no behavioral support, no GI specialist consult is built into either program. You get the medication and the prescriber. If you want structured nutrition and coaching, you need a separate program or you need to add those services.
Dose changes between shipments. If you need to step a dose up or down between monthly shipments, the next shipment typically reflects the new dose without extra charge — but the pricing tier may change.
Returns. Neither program accepts returns. If you discontinue mid-month, you eat the cost of the remaining doses.
Who LillyDirect is best for
- Self-pay patients with a BMI ≥30 (or ≥27 with comorbidity)
- Patients comfortable with vial-and-syringe administration
- Patients who want the strongest molecule by efficacy data
at the lowest manufacturer cash price
- Patients without insurance coverage for anti-obesity drugs
Who NovoCare is best for
- Self-pay patients already established on Wegovy who want to
move from compounded semaglutide to brand-name
- Patients who specifically prefer the Wegovy pen device
- Patients whose prescriber recommends semaglutide
specifically (e.g., for cardiovascular risk reduction benefits where Wegovy has the FDA-approved indication)
Who neither is best for
- Patients with insurance coverage for GLP-1s — use insurance,
it's almost always cheaper
- Patients on Medicare or Medicaid — these programs cannot
enroll federal beneficiaries
- Patients who want substantial behavioral or nutrition
support included — a full-service telehealth program (Mochi or Form Health) is a better structure
- Patients seeking the absolute lowest price — compounded
options through a few telehealth programs can still undercut both manufacturer programs, with the trade-off of not being brand-name product
What the existence of these programs means
The launch of LillyDirect and NovoCare is the manufacturer response to two pressures: political pressure on drug pricing and competitive pressure from compounded GLP-1s. By selling direct, Lilly and Novo cut out the pharmacy benefit manager margin and capture the patient relationship.
For patients, the result is real cash-price reductions on brand-name GLP-1s — reductions that didn't exist 18 months ago. The list price hasn't changed. What's changed is that manufacturers will quietly meet you at a better number if you go through their direct channel.
This is broadly good news for anyone paying out of pocket. It also changes the math for the major telehealth programs, who now have to justify their price premium with services beyond "we'll get you the drug."
If you're shopping GLP-1 programs in 2026, getting a cash quote from LillyDirect is a useful baseline before you evaluate any telehealth offer. If a telehealth program charges more than LillyDirect plus reasonable fees for the care they provide, you should know exactly what you're paying that extra money for.